No gain, no pain: Nav1.7 as an analgesic target

ACS Chemical Neuroscience

Volumn 5, Issue 9, 2014, Pages 749-751

  King, Glenn F ^a   Vetter, Irina ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Analgesic; Chronic pain; Monoclonal antibody; Nav1.7; Nociceptor; Sensory neuron

Indexed keywords

ANALGESIC AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SVMAB1; SODIUM CHANNEL NAV1.7; UNCLASSIFIED DRUG; SCN9A PROTEIN, HUMAN; SODIUM CHANNEL BLOCKING AGENT;

CONGENITAL ANALGESIA; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; ANIMAL; DRUG EFFECTS; GENETICS; METABOLISM; PAIN; SENSORY NERVE CELL;

ANALGESICS; ANIMALS; HUMANS; NAV1.7 VOLTAGE-GATED SODIUM CHANNEL; PAIN; SENSORY RECEPTOR CELLS; SODIUM CHANNEL BLOCKERS;

EID: 84925017869     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn500171p     Document Type: Short Survey

References (5)

1. Gaskin, D. J., and Richard, P. (2012) The economic costs of pain in the United States. J. Pain 13, 715-724.
2. V1.7 sodium channel: From molecule to man. Nat. Rev. Neurosci. 14, 49-62.
3. Theile, J. W., and Cummins, T. R. (2011) Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes. Front. Pharmacol. 2, 54.
4. V1.7 inhibitor from centipede venom with analgesic efficacy exceeding morphine in rodent pain models. Proc. Natl. Acad. Sci. U.S.A. 110, 17534-17539.
5. V1.7 channel voltage sensor for pain and itch relief. Cell 157, 1393-1404.